FAS and Autoimmunity: In vivo work has already been carried out using the BTK inhibitor in the MRL-Fas (lpr) lupus model where it inhibited autoantibody production and the development of kidney disease [23] and in a spontaneous murine model of lupus where it dampened humoral and cellular autoimmunity, as well as lupus nephritis [46].